ADVANCE: Risk of Cardiovascular Disease and Diabetes in Treatment-Naive Patients Initiating Dolutegravir- or Efavirenz-Based ART

March 8-11, 2020; Boston, Massachusetts
Increases in adipose tissue and predicted 10-year risk of diabetes significantly higher with use of DTG + FTC/TAF compared with DTG + FTC/TDF or EFV/FTC/TDF in treatment-naive patients initiating ART in South Africa.
Format: Microsoft PowerPoint (.ppt)
File Size: 189 KB
Released: March 13, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Related Content

Clinical Care Options (CCO): woman’s perspective on her struggle with HIV stigma and why volunteering to help others with HIV has become her purpose

person default Anonymous Patient Released: January 10, 2022

Dr John Baxter and Clinical Care Options (CCO): Transmitted drug resistance does not necessarily preclude the use of many first line ART options.

John D. Baxter, MD Released: January 5, 2022

Expert faculty discuss guideline recommendations for individualizing ART, from Clinical Care Options (CCO)

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD
Program Director
Jean-Michel Molina, MD, PhD Cristina Mussini, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: December 29, 2021 Expired: December 28, 2022

Clinical Care Options (CCO) presents a woman’s perspective on her journey from a late HIV diagnosis to treatment, suppression, and searching for her purpose

person default Anonymous Patient Released: December 27, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings